The Kaiser Family Foundation (KFF) on Wednesday “held a live, interactive webcast to examine recent changes at the Global Fund to Fight AIDS, Tuberculosis and Malaria and the implications for U.S. global health policy,” the foundation reports on its webpage, where a video recording of the webcast is available. “A panel of experts discussed the Global Fund’s recent funding challenges and reorganization, how the U.S. and other donor nations are responding to these changes, and the future outlook for the Fund’s efforts to address HIV, TB, and malaria around the world,” KFF notes (6/13).
The Global Fund to Fight AIDS, Tuberculosis and Malaria on Tuesday released Issue 4 of its newsletter, the “Global Fund News Flash.” The issue features a commentary by Mireille Guigaz, a Global Fund Board member representing France, on the Global Fund’s work in Madagascar, and a piece examining “a Board decision last November that 55 percent of all funding for grant renewals should go to low-income countries,” among other stories (6/19).
Aidspan, an independent watchdog of the Global Fund, on Tuesday published Issue 187 of its “Global Fund Observer.” The issue includes an article on an Office of the Inspector General (OIG) report on its audit of eight Global Fund grants in Kenya; an article examining how reprogramming existing grants can improve their impact; and commentary from Bernard Rivers, executive director of Aidspan, about the Round 2 grants in Kenya (6/5).
The Center for Global Health Policy’s “Science Speaks” blog profiles Bernard Rivers, founder and executive director of Aidspan, a watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, who is leaving his position after 10 years. “He will not be running Aidspan anymore, but plans to continue to research and write about Global Fund issues,” the blog states. In the blog, Rivers discusses his motivation behind founding Aidspan and his hopes for the future of the Global Fund (Barton, 8/30).
“The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases,” according to a Global Fund press release. “Another 11 proposals worth a total of $91.2 million were sent back for revision, and are subject to a further independent technical review before they can be approved,” the press release adds, noting the grant approvals are part of the Transitional Funding Mechanism and “will bridge the financing of essential interventions until the next opportunity to apply for grants” (8/28). According to the U.N. News Centre, the Global Fund “has approved funding of $22.9 billion for more than 1,000 programs in 151 countries, and helped programs provide AIDS treatment for 3.6 million people, anti-tuberculosis treatment for 9.3 million people, and 270 million insecticide-treated nets for the prevention of malaria” (8/28).
Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, on Monday published Issue 193 of its “Global Fund Observer.” The issue features an article announcing the Global Fund’s Transitional Funding Mechanism (TFM) decisions; an article reporting the results of the TFM decisions by country; and an article about a new report from the Global Fund Board on challenges in grant implementation, among others (8/27).
“According to analysis led by Kanika Bahl and Pooja Shaw of Results for Development’s (R4D’s) Market Dynamics team, improved global incentives and information on cost-effectiveness could save the fight against malaria up to $630 million over the next five years and encourage manufacturers to produce better-performing nets,” Bahl, a managing director for R4D, and Shaw, a program officer in the Market Dynamics Practice at R4D, write in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog. “Using their central position in global [long-lasting insecticide-treated net (LLIN)] markets, donor institutions can introduce policy incentives to focus on cost-effectiveness and rationalize specifications so that suppliers can take advantage of economies of scale in production,” they continue, adding, “To implement these policies, global guidance on the performance of various nets is urgently needed, and this is where organizations such as the WHO can provide direction” (8/27).
“[W]e are losing the global fight against bad medicines,” and though “[s]ome progress is being made,” the “problem is that … crackdowns tend to focus on counterfeit drugs” while a “much bigger public health problem … is substandard drugs that are the result of shoddy manufacturing and handling — or perhaps worse, deliberate corner-cutting,” Roger Bate, a resident scholar at the American Enterprise Institute, writes in an opinion piece in The Hill’s “Congress Blog.” He continues, “In poor countries, a frightfully high number of bad drugs reach patients through legitimate supply chains and even donor programs underwritten by U.S. and European taxpayers,” increasing the risk of harm to patients and the development of drug-resistant disease strains.
Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, on Friday published Issue 205 of its “Global Fund Observer.” Among other articles, the issue features an article on the appointment of an interim inspector general; an article summarizing the Global Fund’s year-end estimates on outcome and results; and an article on how the PEPFAR Blueprint highlights areas of cooperation with the Global Fund (12/7).
“On Thursday (Dec. 14), [Nigeria] signed five grant agreements with the Global Fund to Fight AIDS, Tuberculosis and Malaria,” with some of the money going “to provide for antiretroviral therapy treatment and prevention services, particularly on mother-to-child HIV transmission,” Devex’s “The Development Newswire” blog reports. Of the total $335 million, $265 million will go toward HIV/AIDS activities, while $70 million will be used for TB initiatives, the blog notes (Ravelo, 12/14). “For Nigeria, [the] grant agreements address a tremendous need: Nigeria has the second highest number of people living with HIV in the world and only 30 percent of people requiring HIV treatment are receiving antiretroviral therapy,” a Global Fund press release states (12/13).